BURLINGAME, CA / ACCESSWIRE / November 12, 2019 / Humanigen, Inc., (OTC PINK:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on the development of next generation chimeric antigen receptor T cell (CAR-T) and other cell therapies, today announced that two abstracts supporting development of its next generation EphA3-CAR-T program, built on the backbone of ifabotuzumab, the company's proprietary Humaneered anti-EphA3 monoclonal antibody, have been accepted for presentation at the 2019 annual meeting of the Society for Neuro-Oncology (SNO) being held November 20-24, 2019 in Phoenix, AZ.

While CAR-T therapy has revolutionized the treatment landscape for hematological malignancies, its efficacy remains limited in solid tumors. The majority of CAR-T therapies targeting solid tumors have focused on cell surface receptors expressed on tumor cells. However, given the heterogeneity of surface receptor expression on solid tumors and the difficulty of navigating the immunosuppressive stromal microenvironment, strategies to target tumor neovasculature and tumor stromal cells are emerging. Targeting non-transformed, tumor neovasculature and tumor stroma cells may overcome antigen loss and may modulate the suppressive TME. EphA3, an oncofetal antigen, is selectively expressed in tumor neovasculature and tumor stromal cells in brain cancers and other solid tumors making it a novel target for CAR-T development.

The phase I clinical study, led by Prof. Hui Gan and Prof. Andrew Scott from the Olivia Newton-John Cancer Research Institute in Melbourne, Australia, was funded by the Cure Brain Cancer Foundation. The study used radiolabeled ifabotuzumab followed by sequential positron emission tomography (PET) imaging to determine biodistribution, frequency of in situ EphA3 expression and quantitative tumor uptake of ifabotuzumab. The preliminary results include data from eight patients who have been enrolled to date. PET/computed tomography (CT) imaging showed that ifabotuzumab is effectively delivered across the blood-tumor barrier and accumulates specifically at the tumor site in all patients treated to date with no observed normal tissue uptake. Magnetic resonance imaging (MRI) scans showed predominant T2/FLAIR changes, consistent with the treatment effect of ifabotuzumab on tumor vasculature. Treatment emergent adverse events were readily managed with increased premedications after the first occurrence. The abstract is available online at: https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi6/5619490?redirectedFrom=fulltext.

Professors Gan and Scott stated "Our results show that ifabotuzumab is safe and very effective at targeting the tumor. We are also excited that there are early indications that ifabotuzumab may help to control disease growth in some patients."

Using a single chain variable region fragment of ifabotuzumab, a second generation CD28 co-stimulated CAR construct was developed. Using primary patient derived GBM cell lines, the EphA3 CAR-T demonstrated specific and potent anti-tumor activity. Data from in vivo and combinatorial CAR-T experiments will be reported during the oral presentation scheduled on Friday, November 22, 2019 at 4:40pm. The abstract is available online at: https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi88/5619352?redirectedFrom=fulltext.

"These results indicate for the first time that targeting EphA3 with CAR-T cells is feasible, efficacious, and represents a novel therapeutic strategy for solid tumors" stated Dr. Cameron Durrant, CEO of Humanigen. "Our EphA3-CAR-T program as another pillar in our developing cell therapy pipeline. While we continue to develop our GM-CSF neutralization platform with Kite, we are also busy building next generation CAR-T therapies with our combinatorial GM-CSF gene-editing platform and our other CAR-T programs focused on novel tumor targets", Dr. Durrant continued.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company's immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company's proprietary Humaneered anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline. For more information, visit http://www.humanigen.com

Story continues

About the Olivia Newton-John Cancer Research Institute

The Olivia Newton-John Cancer Research Institute is a leader in the development of experimental and breakthrough cancer treatments. We investigate and develop treatments for cancers of the breast, lung, skin, prostate, liver, gastrointestinal tract and brain. Our researchers and clinicians are running more than 120 clinical trials, giving patients access to potential new treatments including immunotherapies and personalized medicine.

Located in Heidelberg, Victoria, Australia, the Institute is integrated within the ONJ Centre, with research laboratories only metres away from where patients are cared for and receive treatment. This inspires and enables the rapid translation of scientific discovery into clinical trial of new, better, cancer treatments.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for future development of lenzilumab to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Black Horse Capital and its affiliates owning more than 50% of our outstanding common stock, including their ability to control the company; our lack of profitability and need for additional capital to operate our business as a going concern; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:

Media:Chris Bowe(646) 662-7628cbowe@humanigen.com

SOURCE: Humanigen, Inc.

View source version on accesswire.com: https://www.accesswire.com/566037/Humanigen-Announces-Two-Abstracts-Accepted-at-the-2019-Annual-Meeting-of-the-Society-for-Neuro-Oncology-including-Oral-Presentation-on-its-Next-Generation-EphA3-CAR-T

Read the rest here:
Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next...

Share

Share

Share

Email

Overview

TMRs report on the Canine Stem Cell Therapy Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services.

Our research report on the Canine Stem Cell Therapy Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Canine Stem Cell Therapy Market over the forecast period. These indicators help businesses pave way in a crowded business landscape, and tread ahead in the competition with confidence.

Further, the report carries out solid groundwork and divulges details ofs share of key segments of the under product, application, and geography.

To ascertain indicators, analysts employed proven research tools and techniques for the same. The analysis of indicators helps business carry out the most strategic planning for competitive advantage. These indicators also help businesses gauge investment proposition and scope of expansion in the Canine Stem Cell Therapy Market over the forecast period.

The report analyzes the competitive landscape of the Canine Stem Cell Therapy Market at length. The section includes detailed insights into key business strategies used by prominent players. Further, the report analyzes impact of growth strategies on the competitive dynamics and valuable insights into share projections of key players in the Canine Stem Cell Therapy Market over the forecast period.

If you are stakeholder in the Canine Stem Cell Therapy Market , the analysis provided will help you understand growth model. Click to get a Brochure report in PDF(including ToC, Tables and Figures).

The report includes an exhaustive list of prominent players in the Canine Stem Cell Therapy Market are VetStem Biopharma, Inc., Regeneus Ltd, Aratana Therapeutics, Inc., VETherapy Corporation, Animal Cell Therapies, Inc., Magellan Stem Cells, and Medrego..

For further know-how of competitive outlook, the report discusses SWOT analysis of prominent players, and how this will impact the competitive hierarchy until the end of the forecast period. This serves as a crucial intelligence indicator to gauge growth strategies adopted by stakeholders, and their stance on mergers, acquisitions, partnerships, and collaborations that can help remain competitive.

Key Questions Answered in the Canine Stem Cell Therapy Market Industry Report

See the original post here:
Canine Stem Cell Therapy Market Analysis and Forecast up to 2026 - Tech Admirers

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade. Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field. The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs. A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment. However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians. A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Read more here:
Canine Stem Cell Therapy Market is Anticipated to Expand at a Healthy CAGR of 4.2% Throughout the Forecast Quantity 2017-2026 - Zebvo

His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

POWAY, Calif. (PRWEB) November 05, 2019

Ole, a German Shepherd, was demonstrating signs of osteoarthritis in April 2019. He was lame and stiff and had difficulty with stairs and jumping. Though his energy level and his willingness to play were normal, it was clear that he was in pain.

Oles owner took him to veterinary surgeon Dr. Holly Mullen of VCA Emergency Animal Hospital and Referral Center in San Diego, California. Dr. Mullen is an experienced VetStem user and has provided VetStem Cell Therapy services for over sixty patients. Upon examination, Dr. Mullen diagnosed Ole with severe osteoarthritis in his hips as a result of hip dysplasia. In patients with joint dysplasia, the affected joint is malformed causing the bone to rub irregularly, which can eventually lead to osteoarthritis. Ole was also diagnosed with osteoarthritis in his lower, or lumbar, spine. It was apparent that these issues were causing Ole discomfort.

In an effort to provide relief, Dr. Mullen recommended Ole receive VetStem Cell Therapy. Adipose-, or fat-derived, stem cell therapy is used by veterinarians to treat osteoarthritis and soft tissue injuries. VetStem Cell Therapy utilizes a patients natural healing cells which may reduce inflammation, block pain, and regenerate damaged joint tissues.

To begin the process, Dr. Mullen extracted fat from Oles abdomen in a minimally invasive anesthetic procedure. The fat was delivered to the VetStem laboratory in Poway, California where it was received and aseptically processed by trained VetStem laboratory technicians. Oles stem cells were extracted and concentrated from his fat tissue and dosed out into an injection that was delivered back to Dr. Mullen. Within 48 hours of the initial fat collection, Ole received one intravenous injection of his own stem cells.

As a follow up to his first injection, Ole received additional stem cell injections approximately two months later. This time he received one injection into each hip, injections along the muscles in his back, as well as an intravenous injection.

In a 90-day post stem cell therapy evaluation (approximately 90 days after the first treatment), Oles owner reported that he was no longer stiff or painful. She also noticed an improvement in his ability to go up and down the stairs, walk, and jump. His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

Dr. Mullens findings were similar at the 90-day examination. She stated, He is doing great! He runs around [the owners] acreage every day with no overt lameness and no signs of painhes strongly ambulatory with a bouncy gait.

Like Ole, many dogs suffer from osteoarthritis and unfortunately, treatment options are somewhat limited. For these patients, VetStem Cell Therapy may be an option. According to owners and veterinarians, greater than 80% of dogs showed an improved quality of life after receiving VetStem Cell Therapy for orthopedic conditions. Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament and joint tissues. In a peer-reviewed study of dogs with chronic osteoarthritis of the hip, it was found that stem cells reduced lameness and pain.

About Holly Mullen, DVM, DACVSDr. Mullen received her DVM from Virginia-Maryland Regional College of Veterinary Medicine in 1985. She completed a small animal medicine and surgery internship as well as a residency in small animal surgery at the Animal Medical Center in New York City. In 1990, she became a board-certified veterinary surgeon. Dr. Mullen has been providing VetStem Cell Therapy for over a decade.

About VetStem Biopharma, Inc.VetStem Biopharma is a veterinarian-led Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Share article on social media or email:

Visit link:
VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web

Canine Stem Cell Therapy market report includes the estimation of market size for value and volume. Further, the report explains statistical forecasts, major trends, regional marketing analysis, and Canine Stem Cell Therapy industry based on Strengths, Weaknesses, industry internal and external environments. Those data are further broken down with manufacturing base distribution, Canine Stem Cell Therapy production area and product type. Major points like market situation and trends, concentration rate mergers, expansion which is basic Canine Stem Cell Therapy information to grow/establish a business is also provided.

Companies operating in the Canine Stem Cell Therapy Market are focusing on merger and acquisitions and new product launches to gain competitive advantage. The Canine Stem Cell Therapy report offers accurately prepared statistics that show the comparison of the aforementioned estimations for all years of the forecast period 2019-2025. numerous factors area unit accountable for the Canine Stem Cell Therapy markets growth, that area unit studied well during this analysis report.

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

Request for Free Sample Copy at: http://www.researchreportcenter.com/request-sample/1258647

United States, China, European Union, Rest of World (Japan, Korea, India and Southeast Asia)

Grab Attractive Discount on this report at: http://www.researchreportcenter.com/check-discount/1258647

Customization of the Report: This report can be customized as per your needs for additional data or countries.Please connect with our sales team (sales@researchreportcenter.com)

See the rest here:
Canine Stem Cell Therapy Market Trends and Analysis to (2019-2025) - Pledge Times

As concerns over antibiotic resistance grow, equine veterinarians look for ways to treat wounds without reaching for these powerful drugs. At the 2019 British Equine Veterinary Association Congress, held Sept. 11-14 in Birmingham, U.K., Dean Hendrickson, DVM, Dipl. ACVS, described ways to do just this, ranging from debridement to stem cell therapy.Debridement

The best way to deal with bacteria is to get rid of them, said Hendrickson, a professor in the Clinical Sciences Department at Colorado State Universitys Veterinary Teaching Hospital, in Fort Collins.

We have a tendency in veterinary medicine to want to kill the bacteria in situ, but Im going to encourage you to remove them and throw them away and dont let the patient have to deal with them at all, he advised the audience.

Veterinarians can remove bacteria through debridement (removing the affected tissue), of which there are several types:

Autolytic debridement. This process uses the bodys own enzymes and moisture to liquefy and remove necrotic (dead) tissue. Hendrickson said its the most selective way to remove bacteria and dead cells while leaving healthy cells.

All youre doing is leaving the healthy wound exudate (liquid the body produces in response to tissue damage) in contact with the wound bed to accomplish this, he said. The normal white blood cells and proteolytic enzymes that occur in wound exudate are your best friends with regard to removing small doses of bacteria and small amounts of necrotic tissue.

To achieve autolytic debridement, you must keep the wound environment moist (but not soupy), which you can do using dressings. If the wound has a lot of necrotic tissue, however, then youll need to use a more aggressive form of debridement, said Hendrickson.

Biological debridement. This method involves using an organism, such as maggots, to remove dead tissue.

It still amazes me how effective maggot debridement is and how rarely we actually use it, said Hendrickson. When a horse comes into the clinic with maggots in its wound, he said people tend to get squeamish and try to remove them, but these guys are doing their jobtheyre getting rid of the necrotic tissue (and pathogenic bacteria). Theres a lot of value to that, and its very rapid and selective.

Enzymatic (chemical) debridement. With this method, veterinarians apply manufactured proteolytic enzymes to the wound to break down devitalized tissue.

This is another great way (to debride wounds), but we dont tend to use it very frequently in veterinary medicine because of the cost of the enzymes, said Hendrickson. Studies have found it to be very effective at reducing bacteria but not as good as autolytic debridement. So the body in and of itself is the best way to go if you have low levels of bacteria.

Mechanical debridement. This technique involves using force to remove tissue. Examples include wet-to-dry dressings and wound irrigation. Its something we do really well in veterinary medicine, almost to a fault, he explained. We scrub, we lavage, and we cause a significant amount of trauma to the wound bed.

On the plus side, mechanical debridement is inexpensive and effective. The downside? It can cause shear stresses to the underlying granulation (scar) tissue, which can lead to further problems down the road, Hendrickson said.

He recommended using the minimal amount of force and pressure necessary.

Sharp debridement. This method involves using tools such as scalpels or curettes to physically remove tissue. Its the most aggressive form of debridement and the most effective way to remove large amounts of bacteria and necrotic tissue, said Hendrickson.

Theres a lot of value to wound debridementthat should be your first step toward reducing bacteria numbers and necrotic tissue, he said. We should not be bathing them with local or systemic antimicrobials. Remove the infected tissue thats there.

Veterinarians can use a variety of debridement dressings to help remove bacteria and dead tissue. Ones Hendrickson said are useful include:

Hypertonic saline. This solution comprises 20% saline, which you can buy commercially or make yourself using salt and water.

The idea is the hypertonic environment created by this saline will kill the bacteria because theyre unable to deal with that environment, and it will also remove the necrotic tissue, Hendrickson said.

While these are highly effective, he said theyre less selective than autolytic, biologic, or enzymatic dressings. He also cautioned against overusing them, because they have the potential to be toxic.

Honey. This substance is both hypertonic and antimicrobial. It can help heal burns, for instance, faster and with fewer adverse effects than other dressings, said Hendrickson.

Researchers have performed a variety of studies confirming the efficacy of honeys such as manuka honey. Further, said Hendrickson, theres some recent evidence out there that shows that local raw honey is more effective at killing local bacteria than medical grade honey.

Polyhexanides (e.g., polyhexamethylene biguanide, or PHMB). Certain sterile antimicrobial dressings are very effective at killing bacteria, even multidrug-resistant varieties. Theyre not antiseptics and should not be confused with them, said Hendrickson.

He then provided the audience with smart antibiotic use tips for when they do need these drugs to combat infection, starting with a sensitivity culture to identify the specific bacteria.

Whether its systemic or local antibiotic therapy, do a culture to know whats happening, then always use the simplest, lowest level of antibiotic possible, he said. While your first dressing might require using an antibiotic you cant pick because you dont know whats there, at least try to get a culture so you can make the decision later on.

Only use antibiotics for short periodstwo weeks or less, he said.

As for topical antibiotics, he recommended using silver dressings or, preferably, triple antibiotic, which hasnt seen much resistance over the decades its been in use.

Hendrickson also reviewed promising studies looking at mesenchymal (embryonic connective tissue) stem cell use in wound treatment: The one place there is evidence for stem cells is in the reduction of bacteria numbers in wounds.

There are lots of ways to reduce bioburden (number of bacteria) in wounds, said Hendrickson. I think wound debridement is the best way to accomplish that. Get rid of the necrotic tissue, and dont use antiseptics in your wounds, because they just create more necrosis, thereby encouraging the number of bacteria forming.

And if you do have to resort to antibiotic administration, choose your antimicrobials well, and use them sparingly, he said.

Go here to read the rest:
Managing Horse Wounds Without Antibiotics - TheHorse.com

Crystal Market Research has recently announced Latest Innovative Report on Global Animal Stem Cell Therapy Market 2025 gives an exact assessment of authentic and current market size, share, income, request, generation, utilization (worth and volume), and market improvement as well as reliable estimations up to 2025. It likewise examines Animal Stem Cell Therapy Market scope, potential, benefit, and attractiveness which significantly studies Industry execution at a moment level. Besides, it reveals insight into competition segmentation, environment and leading organizations that are considered as a portion of the significant features of the market.

In Order To Request For Free Sample Copy Click @https://www.crystalmarketresearch.com/report-sample/HC084561

This Animal Stem Cell Therapy Market study offers a synopsis of the Industry on a global level that helps users in the decision-making processes, which helps to boost their businesses. An exhaustive investigation of the competitive framework of the worldwide Animal Stem Cell Therapy Market has been given, introducing insights into the organization profiles, financial status, ongoing advancements and the SWOT examination.

Get Discount of This Precious Report @ https://www.crystalmarketresearch.com/check-discount/HC084561

Geographically, this Animal Stem Cell Therapy report studies market share and growth opportunity in these key regions, covering:

Get Customised Research Report: https://www.crystalmarketresearch.com/customization/HC084561

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

E-mail: sales@crystalmarketresearch.com | Ph: +1-888-213-4282

Read the original here:
Future Outlook: Animal Stem Cell Therapy Market 2019- 2025| Research Methodologies Offers High Business Outlook growth - Pledge Times

Global 3D Bio-Printing Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global 3D Bio-Printing industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Make An EnquiryAbout This Report @ https://www.researchmoz.us/enquiry.php?type=E&repid=2521299&source=atm

For competitor segment, the report includes global key players of 3D Bio-Printing as well as some small players.

OrganovoCyfuse BiomedicalBioBotsLuxexcel GroupAspect Biosystems3Dynamics SystemsStratasysVoxeljetMaterialiseSolidscape

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeMagnetic LevitationInkjet Based 3D BioprintingSyringe Based 3D BioprintingLaser Based 3D BioprintingOthers

Segment by ApplicationMedicalDentalBiosensorsFood and Animal Product BioprintingOthers

Request Sample Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=2521299&source=atm

Important Key questions answered in 3D Bio-Printing market report:

What will the market growth rate, Overview, and Analysis by Type of 3D Bio-Printing in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in 3D Bio-Printing market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of 3D Bio-Printing market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2521299&licType=S&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe 3D Bio-Printing product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of 3D Bio-Printing , with price, sales, revenue and global market share of 3D Bio-Printing in 2019 and 2015.

Chapter 3, the 3D Bio-Printing competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the 3D Bio-Printing breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, 3D Bio-Printing market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe 3D Bio-Printing sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Continued here:
Trimmers Market Top Impacting Factors to Growth of the Industry by 2025 - Health News Office

Global Canine Stem Cell Therapy Market reports provide in-depth analysis of Top Players, Geography, End users, Applications, Competitor analysis, Revenue, Price, Gross Margin, Market Share, Import-Export data, Trends and Forecast.

Firstly, the Canine Stem Cell Therapy Market Report provides a basic overview of the industry including definitions, classifications, applications and chain structure. The Canine Stem Cell Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

The Global Canine Stem Cell Therapy market report analyzes and researches the Canine Stem Cell Therapy development status and forecast in United States, EU, Japan, China, India and Southeast Asia.

The Global Canine Stem Cell Therapy Market report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

Major players profiled in the report are VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet.

On the basis of products, report split into, Canine Stem Cell Therapy.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes.

Download Exclusive Sample of this Premium Report at https://inforgrowth.com/sample-request/5613749/canine-stem-cell-therapy-market

Key Stakeholders as per this report are Canine Stem Cell Therapy Manufacturers, Canine Stem Cell Therapy Distributors/Traders/Wholesalers, Canine Stem Cell Therapy Subcomponent Manufacturers, Industry Association, Downstream Vendors.

The Canine Stem Cell Therapy industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects are assessed and overall research conclusions offered.

With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Development policies and plans, manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost, price, revenue and gross margins.

The Canine Stem Cell Therapy Market report provides key statistics on the market status of the Canine Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

We can also provide the customized data for separate regions like North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa

Major Points Covered in Table of Contents:

1 Canine Stem Cell Therapy Market Overview

2 Global Canine Stem Cell Therapy Market Competition by Manufacturers

3 Global Canine Stem Cell Therapy Capacity, Production, Revenue (Value) by Region (2012-2017)

4 Global Canine Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region (2012-2017)

5 Global Canine Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

6 Global Canine Stem Cell Therapy Market Analysis by Application

7 Global Canine Stem Cell Therapy Manufacturers Profiles/Analysis

8 Canine Stem Cell Therapy Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Canine Stem Cell Therapy Market Forecast (2017-2022)

Ask Your Queries at https://inforgrowth.com/enquiry/5613749/canine-stem-cell-therapy-market

About InForGrowth:

We are a market-intelligence company formed with the objective of providing clients access to the most relevant and accurate research content for their growth needs. At InForGrowth, we understand Research requirements and help a client in taking informed business critical decisions. Given the complexities and interdependencies of market-intelligence, there is always more than one source to explore and arrive at the right answer. Through our smart search feature and our reliable & trusted publishing partners, we are paving way for a more simplified and relevant research.

Contact:Mr. RohanEmail:sales@inforgrowth.com US: +1-909-329-2808 UK: +44-203-743-1890

More here:
Canine Stem Cell Therapy Market Analysis by Key Players, Types, Applications and Growth Opportunities to 2025 - TheFinanceTime

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and OPKO Health Inc. (NASDAQ:OPK) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Demonstrates Brainstorm Cell Therapeutics Inc. and OPKO Health Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both companies.

Risk & Volatility

Brainstorm Cell Therapeutics Inc.s current beta is 1.19 and it happens to be 19.00% more volatile than S&P 500. OPKO Health Inc.s 2.13 beta is the reason why it is 113.00% more volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Brainstorm Cell Therapeutics Inc. are 1 and 1. Competitively, OPKO Health Inc. has 1.1 and 1 for Current and Quick Ratio. OPKO Health Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

Brainstorm Cell Therapeutics Inc. and OPKO Health Inc. Ratings and Recommendations are available on the next table.

The upside potential is 147.25% for Brainstorm Cell Therapeutics Inc. with consensus target price of $9.

Insider & Institutional Ownership

Brainstorm Cell Therapeutics Inc. and OPKO Health Inc. has shares held by institutional investors as follows: 11.4% and 26.4%. Brainstorm Cell Therapeutics Inc.s share held by insiders are 0.6%. Competitively, insiders own roughly 5.5% of OPKO Health Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance while OPKO Health Inc. has -29.9% weaker performance.

Summary

OPKO Health Inc. beats Brainstorm Cell Therapeutics Inc. on 7 of the 11 factors.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the rest here:
Brainstorm Cell Therapeutics Inc. (BCLI) and OPKO Health Inc. (NASDAQ:OPK) Comparison side by side - MS Wkly